Note: Ingredients listed on restricted chemical lists
EC/CAS
200-661-7/67-63-0
Name of the chemical
Propan-2-ol
Concentration
70
General Information
Version
3.3
Revision date
2023-10-27
Product name
PROCESS2WIPE IPA70
Emergency telephone
+1 610-644-8335, +1 610-644-8336, +91 22-43560400, +44 (0)1235 239 670, +44 (0)1235 239 671, +353 1 809 2566, +353 1 809 2166
Icons in SDS
Company Information
company name
Veltek Associates, Inc
e-mail address of the competent person responsible for the Safety Data Sheet
vai@sterile.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H225, H319, H336
Hazard statements
Code
Statements
H225
Highly Flammable liquid and vapour
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling
Hazard pictograms
GHS02 GHS07
Signal word
Danger
Contains
Isopropanol
Hazard statements
H225 - Highly flammable liquid and vapour. H319 - Causes serious eye irritation. H336 - May cause drowsiness or dizziness.
Precautionary statements
P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. P270 - Do not eat, drink or smoke when using this product. P280 - Wear eye protection, protective gloves, Long sleeved clothing. P305+P351+P338 - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P337+P313 - If eye irritation persists: Get medical advice/attention. P501 - Dispose of contents and container to an authorised waste collection point.
2.3 Other hazards
This substance/mixture does not meet the PBT criteria of REACH regulation, annex XIII This substance/mixture does not meet the vPvB criteria of REACH regulation, annex XIII Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %